Belinostat Patent Expiration
Belinostat is Used for treating relapsed or refractory peripheral T-cell lymphoma (PTCL). It was first introduced by Acrotech Biopharma Inc
Belinostat Patents
Given below is the list of patents protecting Belinostat, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Beleodaq | US8835501 | Pharmaceutical formulations of HDAC inhibitors | Oct 27, 2027 | Acrotech Biopharma |
| Beleodaq | US6888027 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors |
Aug 10, 2026
(Expired) | Acrotech Biopharma |
Belinostat's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Belinostat:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
